Enhertu Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Enhertu market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to the rising prevalence of HER2-positive breast cancer, higher disposable incomes, and an increase in the diagnosis of HER2-positive breast cancer.

The growth projected for the forecast period can be attributed to advancements in healthcare infrastructure, increased investments in research and development, enhanced treatment options driving market expansion, and a growing demand for oral drugs. Key trends during this period include an increase in drug launches, the rise of combination therapies, advancements in targeted therapies, greater use of immunotherapy, a focus on personalized medicine, the development of biosimilars, and a growing number of drug approvals and combination therapy approvals.

The rising prevalence of breast cancer is expected to drive the growth of the Enhertu market in the future. Breast cancer is a type of cancer that originates in the breast cells, often in the milk ducts or lobules, and has the potential to spread to other parts of the body. Factors contributing to the increasing prevalence of breast cancer include an aging population, genetic predispositions, lifestyle factors such as poor diet and lack of physical activity, environmental exposures, and improvements in detection and screening methods. Enhertu offers targeted therapy for breast cancer patients by combining chemotherapy with HER2-targeted treatment, improving outcomes for those with advanced or metastatic HER2-positive breast cancer. For example, Breast Cancer Now, a UK-based charity, reported in September 2023 that approximately 600,000 people in the UK are living after a breast cancer diagnosis, a number expected to double to 1.2 million by 2030. This growing prevalence of breast cancer is fueling the demand for Enhertu.

A significant trend in the Enhertu market is the expansion of its indications through ongoing clinical trials to explore its potential for treating other types of cancer, including non-small cell lung cancer (NSCLC) and colorectal cancer, in addition to its current use in HER2-positive breast cancer. These trials are vital for the development of Enhertu as a targeted treatment, demonstrating notable improvements in progression-free survival for HR-positive, HER2-low metastatic breast cancer patients in the DESTINY-Breast06 Phase 3 trial after undergoing one or more lines of endocrine therapy. In April 2024, Daiichi Sankyo, a Japanese pharmaceutical company, and AstraZeneca, a UK-based pharmaceutical company, announced the results of the DESTINY-Breast06 Phase 3 trial, which showed that Enhertu significantly improves progression-free survival in HR-positive, HER2-low metastatic breast cancer patients who had previously received endocrine therapy. This study is noteworthy as it marks the first time a HER2-directed therapy has shown a meaningful benefit for this patient population.

In November 2024, Daiichi Sankyo entered into a licensing agreement worth $300 million with Alteogene, a South Korean company, to develop a subcutaneous version of Enhertu. The goal of this collaboration is to use Alteogene’s proprietary technologies to create a potentially more convenient and less invasive alternative for patients receiving Enhertu treatment. This partnership highlights the continued efforts to improve the delivery method of Enhertu, making it more accessible to patients in need.

Major companies operating in the enhertu market are AstraZeneca Plc and Daiichi Sankyo Co. Ltd.

North America was the largest region in the enhertu market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in enhertu report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the enhertu market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Enhertu (trastuzumab deruxtecan) is a targeted cancer therapy used to treat adults with HER2-positive breast cancer that is metastatic or cannot be surgically removed. It works by combining a monoclonal antibody (trastuzumab) that targets HER2 with a chemotherapy agent (deruxtecan) that interferes with cancer cell growth.

Enhertu is primarily indicated for HER2-positive metastatic breast cancer, HER2-low metastatic breast cancer, HER2-mutant non-small cell lung cancer (NSCLC), and HER2-positive metastatic gastric cancer. HER2-positive breast cancer refers to a type of breast cancer that tests positive for the human epidermal growth factor receptor 2 (HER2) protein. Treatment lines include first-line, second-line, and third-line therapies, with distribution through hospital pharmacies, specialty pharmacies, and retail pharmacies.

The enhertu market research report is one of a series of new reports that provides enhertu market statistics, including enhertu industry global market size, regional shares, competitors with a enhertu market share, detailed enhertu market segments, market trends, and opportunities, and any further data you may need to thrive in the enhertu industry. This enhertu market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The enhertu market consists of sales of lyophilized powder for injection and IV infusions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.